PT  - JOURNAL ARTICLE
AU  - Yuefei Liu
AU  - Lisa Häussinger
AU  - Jürgen M. Steinacker
AU  - Alexander Dinse-Lambracht
TI  - Association between epidemic dynamics of Covid-19 infection and ABO blood group types
AID  - 10.1101/2020.07.12.20152074
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.12.20152074
4099  - http://medrxiv.org/content/early/2020/07/15/2020.07.12.20152074.short
4100  - http://medrxiv.org/content/early/2020/07/15/2020.07.12.20152074.full
AB  - Background Covid-19 pandemic is the most critical challenge nowadays for the manhood, and the infection and death cases are still speedily increasing. Since there are no available vaccine and specifically effective treatment, to break the infectious way of the pandemic remains the unique measure to efficiently combat Covid-19 infection. Understanding factors that affect the Covid-19 infection can help make better balance between activity restriction and infection dynamics. This study sought to investigate association between Covid-19 infection and blood type distribution.Methods The big data provided by World Health Organization and Johns Hopkins University were taken to assess epidemic dynamics of Covid-19 infection. Growth rate and doubling time of infection and death cases, reproductive number, infection and death cases in the mid-exponential phase were analyzed in relation to blood type distribution.Results Growth rate of infection and death cases correlated significantly to blood type A proportion of the population positively while to blood type B proportion negatively. In comparison with lower blood type A population (< 30%) people with higher blood type A (≥ 30%) had more infection and death cases in the early exponential phase, higher growth rates, and shorter case doubling time for infection and death.Discussion Covid-19 infection is significantly associated with blood type distribution and people with blood type A are more susceptible to Covid-19 infection and have higher epidemic dynamics and higher case fatality rate. The results of this study provide important and useful information for fighting Covid-19 pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No ethics committee approvals necessary since data used are from public access.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWorld Health Organization Johns Hopkins University https://www.who.int https://coronavirus.jhu.edu/map.html